UK Markets open in 1 min

Vifor Pharma AG (0RPD.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
135.50-1.65 (-1.20%)
At close: 05:19PM BST
Full screen
Previous close137.15
Bid0.00 x 0
Ask0.00 x 0
Day's range135.20 - 137.40
52-week range135.20 - 137.40
Avg. volumeN/A
Market cap8.777B
Beta (5Y monthly)1.36
PE ratio (TTM)21.16
EPS (TTM)6.40
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Update on the timeline for Vifor Pharma tender offer

    ST. GALLEN, Switzerland, May 12, 2022--Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. While some antitrust authorities have approved the transaction, some approvals are still outstanding.

  • Business Wire

    Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

    ST. GALLEN, Switzerland & STAMFORD, Conn., April 28, 2022--Regulatory News: This press release features multimedia. View the full release here:

  • Business Wire

    94th Vifor Pharma Group Annual General Meeting

    ST. GALLEN, Switzerland, April 26, 2022--Regulatory News: At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and the COVID-19 Act and has been reconfirmed in view of the current status of the tender offer launched by CSL Behring AG. Shareholders exercised their rights exclusively through the independent proxy.